Elite Trades From Anywhere

$100 Off Your First Year

00
Days
00
Hours
00
Mins
00
Sec
Claim Now
Last Close
2.40
Jul 02 • 10:44AM ET Dollar change+0.01 Percentage change(0.63%)
Index
RUT
Market Cap
348.65M
Enterprise Value
319.25M
Income
-54.29M
Sales
28.94M
Book/sh
1.81
Cash/sh
0.34
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
89
IPO
Sep 30, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
12.05
P/B
1.33
P/C
7.11
P/FCF
-
EV/EBITDA
-
EV/Sales
11.03
Quick Ratio
4.73
Current Ratio
4.80
Debt/Eq
0.07
LT Debt/Eq
0.06
Option/Short
Yes / Yes
EPS (ttm)
-0.46
EPS next Y
-0.27
EPS next Q
-0.12
EPS this Y
28.32%
EPS next Y
34.73%
EPS next 5Y
38.90%
EPS past 3/5Y
-29.62% -14.88%
Sales past 3/5Y
-31.89% -14.39%
EPS Y/Y TTM
21.41%
Sales Y/Y TTM
8.21%
EPS Q/Q
65.12%
Sales Q/Q
247.30%
Insider Own
18.54%
Insider Trans
-0.44%
Inst Own
47.21%
Inst Trans
-11.56%
ROA
-18.10%
ROE
-20.25%
ROIC
-19.50%
Gross Margin
15.20%
Oper. Margin
-203.13%
Profit Margin
-187.59%
SMA20
2.13%
SMA50
12.80%
SMA200
31.08%
Trades
Shs Outstand
144.78M
Shs Float
118.09M
52W High
2.79 -13.80%
52W Low
1.30 85.00%
Volatility
8.37% 8.53%
ATR (14)
0.18
RSI (14)
53.43
Beta
0.44
Rel Volume
0.25
Avg Volume
734.28K
Volume
42,587
Perf Week
-4.18%
Perf Month
-8.21%
Perf Quarter
54.17%
Perf Half Y
29.30%
Perf YTD
30.00%
Perf Year
29.30%
Perf 3Y
-52.19%
Perf 5Y
-
Perf 10Y
-
Prev Close
2.39
Price
2.40
Change
0.63%
Date Action Analyst Rating Change Price Target Change
Nov-29-23Initiated RBC Capital Mkts Outperform $6
Apr-21-23Initiated The Benchmark Company Buy $8
Apr-13-23Initiated Craig Hallum Buy $10
Feb-22-23Initiated Cowen Outperform $10
Feb-13-23Initiated H.C. Wainwright Buy $11
Dec-20-22Initiated Truist Buy $10
Dec-16-22Initiated Credit Suisse Outperform $13
Nov-29-22Initiated SVB Leerink Outperform $6
Nov-28-22Initiated Stifel Buy $12
May-08-26 08:30AM
May-07-26 04:05PM
May-06-26 09:33AM
Apr-24-26 08:00AM
Apr-21-26 08:00AM
08:30AM Loading…
Mar-05-26 08:30AM
12:02AM
Mar-04-26 07:57PM
05:55PM
04:05PM
Mar-03-26 07:20AM
Feb-24-26 08:00AM
Feb-19-26 08:00AM
Dec-15-25 04:05PM
Dec-11-25 10:17AM
04:05PM Loading…
Dec-04-25 04:05PM
Nov-17-25 05:23PM
Nov-05-25 12:06AM
Nov-04-25 06:35PM
04:05PM
Nov-03-25 08:07AM
Oct-30-25 10:00AM
Oct-28-25 10:00AM
Oct-16-25 08:55AM
08:00AM
Oct-14-25 08:00AM
Sep-02-25 08:00AM
Aug-25-25 07:00AM
Aug-06-25 06:15PM
04:05PM
10:26AM Loading…
Aug-05-25 10:26AM
Jul-16-25 08:00AM
Jun-30-25 09:50AM
May-13-25 04:05PM
May-09-25 08:31AM
May-08-25 05:40PM
04:06PM
04:05PM
May-05-25 12:59PM
May-01-25 08:00AM
Apr-21-25 08:00AM
Apr-14-25 08:00AM
Mar-18-25 04:05PM
Feb-24-25 08:00AM
Feb-03-25 04:57PM
Dec-16-24 04:15PM
Nov-12-24 04:05PM
Oct-30-24 08:00AM
Oct-22-24 08:00AM
Aug-26-24 08:00AM
Aug-08-24 04:05PM
Jul-25-24 08:00AM
Jun-03-24 04:05PM
May-20-24 08:05AM
May-15-24 04:05PM
May-12-24 03:24PM
May-09-24 08:56PM
04:05PM
May-01-24 08:00AM
Apr-22-24 08:00AM
Mar-21-24 11:31AM
Mar-20-24 08:54PM
04:05PM
Feb-28-24 08:27AM
Feb-26-24 08:00AM
Feb-20-24 08:00AM
Dec-14-23 04:30PM
Nov-20-23 12:39PM
Nov-14-23 05:03AM
Nov-09-23 05:55PM
09:24AM
08:00AM
Nov-02-23 08:00AM
Nov-01-23 09:00AM
Oct-31-23 04:28PM
Oct-26-23 02:32PM
Oct-12-23 08:00AM
Sep-05-23 08:00AM
Aug-15-23 05:20AM
Aug-13-23 08:06AM
Aug-10-23 04:05PM
Aug-07-23 04:05PM
Jul-31-23 08:00AM
Jul-17-23 07:35AM
Jun-13-23 06:00AM
May-18-23 05:09PM
May-17-23 04:05PM
May-16-23 06:06AM
May-14-23 08:03AM
May-11-23 10:55PM
07:00AM
May-05-23 07:14AM
May-04-23 06:26AM
May-01-23 08:00AM
Apr-26-23 08:01PM
Apr-25-23 08:00AM
Apr-19-23 08:30AM
Apr-07-23 10:24PM
Apr-05-23 06:09AM
Apr-02-23 08:51AM
OmniAb, Inc. operates as a drug discovery company. The firm focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
PresidentMr. Matthew W. Foehr
Executive VP of Finance & CFOMr. Kurt A. Gustafson
Chief Legal Officer & SecretaryMr. Charles S. Berkman J.D.
Senior Vice President of People & TalentMs. Cia McCaffrey
Senior Vice President of Antibody DiscoveryDr. Bill Harriman Ph.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GUSTAFSON KURT AOfficerApr 07 '26Proposed Sale1.496,91310,266Apr 07 08:33 PM
FOEHR MATTHEW WPresident and CEOApr 07 '26Option Exercise0.0036,45904,439,736Apr 07 08:26 PM
FOEHR MATTHEW WPresident and CEOApr 07 '26Sale1.4919,24428,6744,420,492Apr 07 08:26 PM
FOEHR MATTHEW WOfficerApr 07 '26Proposed Sale1.4919,24428,577Apr 07 08:25 PM
GUSTAFSON KURT AExecutive VP, Finance and CFOApr 07 '26Option Exercise0.0013,5420268,396Apr 07 08:25 PM
GUSTAFSON KURT AExecutive VP, Finance and CFOApr 07 '26Sale1.496,91310,300261,483Apr 07 08:25 PM
Berkman Charles SChief Legal OfficerApr 07 '26Option Exercise0.0013,5420406,242Apr 07 08:23 PM
Berkman Charles SChief Legal OfficerApr 07 '26Sale1.497,15710,664399,085Apr 07 08:23 PM
Berkman Charles SOfficerApr 07 '26Proposed Sale1.497,15710,628Apr 07 08:12 PM
Berkman Charles SChief Legal OfficerFeb 18 '26Option Exercise0.0018,7500402,373Feb 18 06:36 PM
Berkman Charles SChief Legal OfficerFeb 18 '26Sale1.719,67316,541392,700Feb 18 06:36 PM
GUSTAFSON KURT AExecutive VP, Finance and CFOFeb 18 '26Option Exercise0.0018,7500278,152Feb 18 06:35 PM
GUSTAFSON KURT AExecutive VP, Finance and CFOFeb 18 '26Sale1.719,30115,905268,851Feb 18 06:35 PM
FOEHR MATTHEW WPresident and CEOFeb 18 '26Sale1.7130,84352,7424,403,277Feb 18 06:34 PM
FOEHR MATTHEW WPresident and CEOFeb 16 '26Option Exercise0.0036,45804,396,541Feb 17 06:22 PM
FOEHR MATTHEW WPresident and CEOFeb 17 '26Sale1.7020,75435,2824,375,787Feb 17 06:22 PM
GUSTAFSON KURT AExecutive VP, Finance and CFOFeb 16 '26Option Exercise0.0013,5420266,230Feb 17 06:20 PM
GUSTAFSON KURT AExecutive VP, Finance and CFOFeb 17 '26Sale1.706,82811,608259,402Feb 17 06:20 PM
Berkman Charles SChief Legal OfficerFeb 16 '26Option Exercise0.0013,5420390,613Feb 17 06:18 PM
Berkman Charles SChief Legal OfficerFeb 17 '26Sale1.706,99011,883383,623Feb 17 06:18 PM
FOEHR MATTHEW WOfficerFeb 17 '26Proposed Sale1.7020,48334,821Feb 17 04:33 PM
Berkman Charles SOfficerFeb 17 '26Proposed Sale1.706,89111,715Feb 17 04:29 PM
GUSTAFSON KURT AOfficerFeb 17 '26Proposed Sale1.706,89111,715Feb 17 04:27 PM
Berkman Charles SChief Legal OfficerDec 07 '25Option Exercise0.0015,6210385,115Dec 09 09:02 AM
Berkman Charles SChief Legal OfficerDec 08 '25Sale1.968,04415,766377,071Dec 09 09:02 AM
GUSTAFSON KURT AExecutive VP, Finance and CFODec 07 '25Option Exercise0.0046,5000276,610Dec 09 09:02 AM
GUSTAFSON KURT AExecutive VP, Finance and CFODec 08 '25Sale1.9623,92246,887252,688Dec 09 09:02 AM
FOEHR MATTHEW WPresident and CEODec 07 '25Option Exercise0.0026,55404,373,749Dec 09 09:01 AM
FOEHR MATTHEW WPresident and CEODec 08 '25Sale1.9613,66626,7854,360,083Dec 09 09:01 AM
GUSTAFSON KURT AOfficerDec 08 '25Proposed Sale1.9623,92246,910Dec 08 07:17 PM
FOEHR MATTHEW WOfficerDec 08 '25Proposed Sale1.9613,66626,798Dec 08 07:15 PM
Berkman Charles SOfficerDec 08 '25Proposed Sale1.968,04415,774Dec 08 07:14 PM
HIGGINS JOHN LDirectorNov 07 '25Buy1.3841,03856,6322,929,148Nov 10 08:30 AM
HIGGINS JOHN LDirectorNov 06 '25Buy1.4136,22351,0742,888,110Nov 10 08:30 AM